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Matalonga et alIt is estimated that 350 million individuals worldwide expe-
rience one of approximately 7000 existing rare diseases
(RDs).1 The low prevalence of each disease and the high
heterogeneity and variability of clinical symptoms make
diagnosis and accessibility to appropriate treatment a real
challenge. As emphasized by the International Rare Disease
Research Consortium, progress in this field requires identi-
fication of RDs and their causes to develop appropriate
treatments,2 and as 80% of RDs are thought to have a genetic
origin, particular emphasis has been placed on the rapidly
expanding development of genomic technologies. The next-
generation sequencing era has enabled cost-effective
sequencing of RD patients’ exomes or genomes, bringing
these approaches into diagnostics.3 However, the interpreta-
tion of the genome is still a real challenge for molecular
geneticists, and innovative bioinformatics solutions
combining genomic and clinical data are crucial for reaching
a diagnosis.4,5 Data sharing and analysis platforms, such as
the RD-Connect Genome-Phenome Analysis Platform
(GPAP; https://platform.rd-connect.eu, registration required,
last accessed May 9, 2020),5,6 have emerged to provide
methods and standardized analyses of phenotypic and (gen)
omic data to facilitate the mutation detection processes.
Autozygosity, as a result of consanguineous mating, has
long been known to be a risk factor for RDs of genetic
origin through a variety of effects, such as reduction in
genetic variation, increased frequency of homozygous ge-
notypes for deleterious alleles, and lower population
viability.7 The deleterious consequences in populations with
higher prevalence of consanguinity, due to physical or
cultural isolation, have been widely reported (reviewed in
Fareed and Afzal8), and many rare recessive disease genes
have been identified by homozygosity mapping in which
large regions flanking the disease-causing variant are ex-
pected to be identical by descent in affected individuals
whose parents are related.9,10 In addition, about one-third of
autosomal recessive rare disorders occurring in families with
no known consanguinity are caused by homozygous vari-
ants located in regions likely identical by descent.11
Next-generation sequencing technologies allow precise
detection of genomic regions where a reduction in hetero-
zygosity is evident and offer the opportunity to estimate
autozygosity at the exome and genome level.12 Different
software, such as HomozygosityMapper,13 PLINK,14
HomSI,15 and H3M2,16 has been developed for the detec-
tion of runs of homozygosity (ROHs) from exome and
genome sequencing data.12,17 The identification of autozy-
gous regions through the detection of contiguous lengths of
homozygous segments of the genome where the two hap-
lotypes inherited are identical has been applied in multiple
population genomic studies (reviewed in Ceballos et al18).
Different homozygosity mapping software presents specific
advantages and limitations, as reviewed in Howrigan et al19
and Oliveira et al20. Part of the limitations encompass the
use of exome sequencing (ES), which by definition frag-
ments genomic data, thus interfering with the identification1206of homozygous regions. Recently, optimized protocols for
homozygosity mapping based on ES and using PLINK
software have been published, with promising results.10,21,22
Herein, we report on the integration of genomic analysis
and autozygosity assessment on the basis of the detection of
long [>1 megabase (Mb)] ROHs in >2400 ES data sets
from the RD-Connect GPAP. A subset of these measure-
ments was used to generate a model to determine the like-
lihood of an individual being the offspring of
consanguineous parents. To assess this approach, in-
dividuals were classified according to these consanguinity
ranges, and a subset of consanguineous offspring was sub-
sequently analyzed in the RD-Connect GPAP, applying
ROH-specific region filtering to identify the disease-causing
variant(s). To our knowledge, this is the first study
providing thresholds based on total ROH length to estimate
consanguinity from ES data regardless of sequencing center
and protocol used and the largest study attempting to
combine ES and ROH detection approaches to identify
genetic defects of different types of RDs, reaching a diag-
nostic yield of 52% in consanguineous probands.
The consanguinity ranges defined herein for ES data will
facilitate inbreeding estimation in clinical laboratories and
enable confirmation, or (re)classification, of consanguineous
cases, hence increasing the efficiency of molecular diag-
nosis and reporting on secondary consanguinity findings, as
recommended by American College of Medical Genetics
and Genomics (ACMG) guidelines.23
Materials and Methods
Subjects
This study includes clinical and genomic data from 2432
individuals collated within the RD-Connect GPAP (data
set C) (Figure 1) and 76 individuals from an independent
project, the Undiagnosed Rare Disease Program of Cata-
lonia (URDCAT; https://www.urdcat.cat/home, last
accessed May 9, 2020) (data set B) (Figure 1). Clinical
information concerning reported consanguinity and
ethnicity classification, according to the Ontology of
Precision Medicine and Investigation (OPMI; http://www.
ontobee.org/ontology/OPMI, last accessed December 1,
2019) database, were obtained for each individual,
where available. As required by the RD-Connect and
URDCAT adherence agreements, patient consent allowing
the sharing of pseudonymized clinical information with
international collaborators and researchers was obtained
for all individuals included in this study. This study ad-
heres to the principles set out in the Declaration of
Helsinki.
Data Sets Used to Establish the Consanguinity Model
Different data sets and subsets were used to train, test, and
apply the model described in this study (Figure 1). Data setjmd.amjpathol.org - The Journal of Molecular Diagnostics
Consanguinity Detection for DiagnosisA, referred to as training data set, includes 199 index
cases for which presence/absence of consanguinity was
determined by kinship analysis and was used to define the
logistic regression model. Data set B, referred to as testing
data set, includes 76 index cases from URDCAT for which
presence/absence of consanguinity status was determined by
kinship analysis and was used to test our model. Data set C,
referred to as whole data set, includes 2432 individuals (index
cases and relatives) from the RD-Connect GPAP towhich our
model was applied. Finally, data set D, referred to as diag-
nostic data set, includes 79 index cases from data set C in
which genomic data were combined with ROH results to
identify the pathogenic variants responsible for different types
of RDs.Genomic Data Processing
In total, ES data derived from 2432 individuals from
RD-Connect GPAP, sequenced using six different exome
capture kit protocols [Nextera Rapid Exome (Illumina, San
Diego, CA), Nimblegen SeqCap EZ MedExome (Roche,
Basel, Switzerland), SureSelect version 5 (Agilent, Santa
Clara, CA), Broad Custom Exome (Broad Institute, Cam-
bridge, MA), Nextera Expanded Exome (Illumina), and
Illumina TruSeq Expanded Exome], with target capture
sizes ranging from 37 Mb to 62 Mb, and 76 individuals
from URDCAT, sequenced using five different exome
capture kit protocols [Nimblegen SeqCapEZ Exome
(Roche) and Agilent SureSelect version 3, version 4, version
5, and version 6 (Agilent)], with target capture sizes ranging
from 50 to 64 Mb, were included in the study. In all cases,
sequencing reads were processed using the RD-Connect
GPAP standardized analysis pipeline based on GATK3.6
best practices, as described in Laurie et al,24 and the resul-
tant variant calls were used for ROH detection and made
available for analysis through the RD-Connect GPAP.The Journal of Molecular Diagnostics - jmd.amjpathol.orgDetection of Homozygous Regions
Quality filtering of the processed data (VCF files) was
performed to minimize the impact of low-quality variant
calls resulting from sequencing artifacts, misalignment, or
low coverage. Insertions/deletions were discounted, and
only single-nucleotide variants covered by a minimum read
depth of 10 reads and a genotype quality of at least 90 were
included in the analysis. For each individual, ROHs were
identified using PLINK version 1.9014-homozyg option,
applying the optimal parameters defined by Kancheva
et al,21. This method is designed for whole exome
sequencing data and assumes intronic and intergenic regions
to be homozygous when surrounded by two detected ho-
mozygous coding regions.21 PLINK was run for each
sample to identify ROH size with a minimum length of 1
Mb to exclude common shorter ROHs. Plots were generated
using RStudio version 1.0.143 (RStudio, Boston, MA).
Establishing Consanguinity Ranges for ES Data
For this study, consanguineous individuals were defined as
being the offspring of third degree (equivalent to being first
cousins) or more closely related parents (ie, having a kinship
coefficient >0.045).25 To build a logistic regression model
to predict if an individual is likely to be a consanguineous
offspring according to the total ROH size, we first identified
a subset of samples for which presence or absence of con-
sanguinity had been clinically reported and subsequently
experimentally confirmed by trio kinship analysis using
-relatedness2 from vcftools. In total, 98 index cases were
confirmed as consanguineous offspring (kinship
coefficient > 0.045) and 101 were confirmed as non-
consanguineous (kinship coefficient < 0.045). These cases
(199 in total) were included in data set A (Figure 1), referred
as training data set. Two thirds of data set A, 62 consan-
guineous cases and 66 nonconsanguineous cases, was usedFigure 1 Description of the different data sets used in
this study. Data sets used to train, test, and evaluate the
model described in this study. Data set A, referred to as
training data set, includes 199 index cases for which
presence or absence of consanguinity was determined by
kinship analysis and was used to define the logistic
regression model. Data set B, referred to as testing data
set, includes 76 index cases from the Undiagnosed Rare
Disease Program of Catalonia (URDCAT) for which the
presence or absence of consanguinity status was deter-
mined by kinship analysis and was used to test our model.
Data set C, referred to as whole data set, includes 2432
individuals (index cases and relatives) from the Rare
Disease (RD)eConnect Genome-Phenome Analysis Plat-
form (GPAP) to which our model was applied. Data set D,
referred to as diagnostic data set, includes 79 index cases
in which genomic data were combined with run of ho-
mozygosity results to identify the pathogenic variants
responsible for different types of rare disease.
1207
Figure 2 Consanguinity model and ranges defined using the training data set. A: Distribution of the total run of homozygosity (ROH) size across samples
from the training data set (199 individuals) for which presence or absence of consanguinity was determined by kinship analysis. B: Linear regression model
used to define the probability of consanguinity on the basis of total ROH size per sample of the training data set. Sensitivity, specificity, and accuracy of the
model have been calculated by analyzing the Undiagnosed Rare Disease Program of Catalonia testing data set (Supplemental Table S1). C: Total ROH size
distribution of the training data set, categorized by the different ethnicities reported. D: Total ROH size distribution of the training data set, categorized by
exome capture kits. Colors indicate the presence (orange) or absence (gray) of consanguinity for an individual, as determined by kinship analysis of the
parents (third-degree or closer relation classified as consanguineous); and dotted red lines, the defined consanguinity thresholds [22, 79, and 123 megabases
(Mb)]. Points C1 to C5 indicate the five nonconsanguineous cases incorrectly classified as (probably) consanguineous (Supplemental Table S2). n Z 98
consanguineous samples (A); n Z 101 nonconsanguineous samples (A).
Matalonga et alto train a logistic model, and the remaining 71 samples were
used to define four consanguinity ranges: non-
consanguineous (consanguinity probability < 0.05), uncer-
tain (0.05 < consanguinity probability < 0.5), probably
consanguineous (0.5 < consanguinity probability < 0.95),
and consanguineous (consanguinity probability > 0.95).
The accuracy of the model is 98%, with a P value of 0.05.
Precision of the Consanguinity Model
The specificity, sensitivity, and accuracy of the model for
predicting consanguinity status was evaluated using data set
B, referred to as testing data set (Figure 1), which includes 76
index cases from URDCAT for which presence or absence of
consanguinity status was determined by kinship analysis.
Genomic Data Analysis and Interpretation
Genomic data were analyzed using the RD-Connect GPAP,
which enables the combination of variant filtering and ho-
mozygosity mapping. Identification of putative disease-
causing variants in consanguineous or probably consan-
guineous individuals was achieved by applying the
following filters: homozygous variant, minimum depth of
coverage of 10, variants classified as having a high1208(disruptive) or moderate (amino acid change) impact on the
protein, according to SnpEff, and observed population allele
frequency <0.02, according to gnomAD,26 ExAC,27 and
1000 Genomes Project28 databases. When no interesting
variants were identified, other inheritances and genotypes
were assessed (eg, autosomal recessive inheritance associ-
ated with compound heterozygous variants and X-linked
inheritance). Candidate variants were classified following
the ACMG standards and guidelines for interpretation29 and
proposed to the corresponding submitter for confirmation of
molecular diagnosis.
Statistical Analysis
A paired samples Wilcoxon test was performed for the
comparison of the number of rare homozygous variant with
or without applying a 1-Mb ROH filter. Statistical signifi-
cance was determined as P < 0.05.
Results
Consanguinity Model and Ranges
To predict if an individual is likely to be a consanguineous
offspring, according to the total ROH size identified from ESjmd.amjpathol.org - The Journal of Molecular Diagnostics
Table 1 Consanguinity Classification, According to the Model
Described in This Study





79e123 2.9e4-6 Probably consanguineous
22e79 0.8e2.9 Uncertain
<22 <0.8 Nonconsanguineous
*Froh is defined as the percentage of the genome that is homozygous
compared with the total autosomal genomic length (approximately 2691
Mb for GRCh37/hg19).
Mb, megabase; ROH, run of homozygosity.
Consanguinity Detection for Diagnosisdata, we analyzed ROH results from data set A, the training
data set (Figure 1 and Figure 2A). Consanguinity was defined
as unions contracted between individuals biologically related
as first cousins (equivalent to third-degree relationship) or
closer. We built a logistic regression model to define the
probability of consanguinity according to the total ROH size
identified by ROH analysis (Figure 2B). We used this model
and probabilities of being a consanguineous offspring of 5%,
50%, and 95% to define four consanguinity ranges: non-
consanguineous (total ROH size < 22 Mb), uncertain
(22 Mb < total ROH size < 79 Mb), probably consanguin-
eous (79 Mb < total ROH size < 123 Mb), and consan-
guineous (total ROH size > 123 Mb) (Table 1). If we
consider the percentage of the genome that is homozygous
(Froh) assuming a total autosomal genomic length of 2691
Mb for GRCh37/hg19 (https://www.ncbi.nlm.nih.gov/
assembly, accession number GRCh38.p13), consanguinity
ranges can be extrapolated as follows: nonconsanguineous
(Froh < 0.8% of the genome), uncertain (0.8% < Froh
< 2.9%), probably consanguineous (2.9% < Froh < 4.
6%), and consanguineous (total ROH size > 4.6%)
(Table 1). The robustness of this approach was tested using
an independent data set B, defined as testing data set
(Figure 1). The sensitivity (true-positive rate), specificity
(true-negative rate), and accuracy (degree of closeness to a
true value) of the test were 80%, 99%, and 97%, respectively
(Figure 2B and Supplemental Table S1). According to the
established thresholds, 194 of the 199 cases included in the
training data set were correctly classified, and five non-
consanguineous cases were incorrectly classified as (prob-
ably) consanguineous (Supplemental Table S2). Two of the
five cases (C4 and C5) having a total ROH size of 82.4 and 80
Mb, respectively, were close to the defined threshold of 79
Mb. All cases presented an ES median coverage between 57
and 94.Ethnicity Effect on Total ROH Size Detection
In some populations in North Africa, West Asia, or South
India, consanguineous marriages are culturally and socially
favored. This fact, together with existing consanguinity inThe Journal of Molecular Diagnostics - jmd.amjpathol.orgisolated populations, results in almost 10% of the world
population either being married to a biological relative or
being a consanguineous offspring.8 To know to which
extent population origin may affect the consanguinity
ranges defined above, total ROH size per individual was
assessed across the different ethnicities reported in the
training data set (Figure 2C). When analyzing the non-
consanguineous cohort across different ethnicities, total
ROH size medians were, as expected, within the non-
consanguineous range for European, Latin American, and
Middle Eastern individuals (Figure 2C). The median total
ROH size was above the nonconsanguineous range in two
different ethnicities: Arabs and Asians. Indeed, two of the
incorrectly classified cases mentioned above (C2 and C3)
(Supplemental Table S2) are of Asian origin. However,
because of the scarce number of individuals in each of these
nonconsanguineous data sets (Arabs Z 2, and Asians Z 3)
(Supplemental Table S3), results were not confirmed sta-
tistically. Similar tendencies were observed when analyzing
the mean length of the homozygous segments by ethnicity
(Supplemental Table S3).
Effect of Exome Capture Kit on Detected Total ROH Size
The algorithm used herein to identify ROH regions uses a
sliding window that scans along single-nucleotide variant
data to detect nonheterozygous stretches. ES experiments
target the evaluation of specific regions of the genome that
differ between exome capture kits. It was hypothesized that
the regions captured in each exome capture kit might affect
the total ROH size, and thus interfere with the determination
of consanguinity status using the ranges identified above.
Therefore, we analyzed the total ROH size across the exome
capture kits from the training data set. Six different exome
capture kits with target capture sizes ranging from 37 to 62
Mb were assessed (Figure 2D). When analyzing the non-
consanguineous cohort across the different exome capture
kits, all total ROH size medians were, as expected, within
the nonconsanguineous range for all of the kits tested.
Similar results were observed when analyzing the mean
length of the segments by exome capture kit (Supplemental
Table S3).
Consanguinity Model Assessment
The consanguinity ranges defined in the first part of this
study were applied to the whole data set (Figure 1), 2432
individuals (index cases and relatives) from the RD-Connect
GPAP. Total ROH size was computed for each individual
and classified according to the comparison of the consan-
guinity status experimentally conferred and its correspond-
ing clinical record. Individuals were classified as
consanguineous or nonconsanguineous when no discrep-
ancies were found between clinical records and experi-
mental conferred consanguinity status. Otherwise, three
types of discrepancies were defined: discrepancy type A,1209
Matalonga et alwhen the individual was reported as consanguineous but
experimentally classified as uncertain or non-
consanguineous; discrepancy type B, when the individual
was reported as of unknown consanguinity but experimen-
tally classified as probably consanguineous or consanguin-
eous; and discrepancy type C, when the individual was
reported as nonconsanguineous but experimentally classi-
fied as probably consanguineous or consanguineous
(Figure 3A). According to our model, consanguinity was
confirmed in 219 of 295 reported cases (74%) and enabled
the reclassification of 95 individuals: 76 individuals (3.1%)
from consanguineous to nonconsanguineous status
(discrepancy type A) and 19 individuals (0.8%) from non-
consanguineous to consanguineous status (discrepancy type
C). Moreover, the model was able to detect and classify 217
potential consanguineous cases (8.9% of the data, discrep-
ancy type B) (Figure 3B). Individuals were also clustered by
exome capture kit and ethnicity (Supplemental Figure S1).
No significant differences were found among the non-
consanguineous cohort between the different exome capture
kits (Supplemental Figure S1A). Nonconsanguineous
Arabs, Asians, and Latin Americans showed a tendency of
increased total ROH size compared with European pop-
ulations (Supplemental Figure S1B).
Uniparental Disomy Assessment
To identify complete uniparental disomy, samples with at
least one ROH >30 Mb were further analyzed. A total of 22Figure 3 Consanguinity model assessment through the analysis of 2432 ES da
data sets, classified according to the comparison of the consanguinity status e
dividuals are classified as consanguineous (C; orange) when stated in the clinical
as consanguineous in the clinical record and experimentally conferred as uncertain
of unknown consanguinity in the clinical record (Unknown) and experimentally c
when stated as nonconsanguineous in the clinical record and experimentally con
experimentally conferred consanguinity range as a function of the consanguinity s
consanguinity thresholds (22, 79, and 123 megabases). discrp., discrepancy type
1210samples from 2432 met that criterion (0.9%) (Supplemental
Table S4). In eight of these samples, the corresponding runs
represented >30% of the total ROH size detected in that
sample. All eight individuals were classified as consan-
guineous or likely consanguineous, according to our model,
and four were index cases affected by a rare disorder.
Application to Molecular Diagnostics Workflow
To assess the impact of proper identification of consan-
guinity and the usage of ROH for diagnosis, we analyzed a
subset of 79 undiagnosed index cases from the whole data
set, which were consanguineous or had a discrepant
consanguineous status (diagnostic data set) (Figure 1).
When applying our model classification to this diagnostic
data set, consanguinity was confirmed in 44 of 60 reported
cases (73%), and 35 individuals were reclassified: 16 in-
dividuals (46% of reclassified) from consanguineous to
nonconsanguineous status (discrepancy type A), 5 in-
dividuals (14% of reclassified) from nonconsanguineous to
consanguineous status (discrepancy type C), and 14 in-
dividuals (40% of reclassified) from unknown to consan-
guineous status (discrepancy type B). On the basis of these
results, we used the RD-Connect GPAP to conduct variant
filtering with or without homozygosity mapping (ROH
region > 1 Mb) in all 79 cases from the diagnostic data set.
The number of resulting candidate variants was counted for
each individual, and results showed an overall 50% decrease
of the number of variants to be further evaluated whenta sets. A: Distribution of the total ROH size across 2432 exome sequencing
xperimentally conferred and that of the corresponding clinical record. In-
record and conferred experimentally; discrepancy type A (blue) when stated
(U) or nonconsanguineous (NC); discrepancy type B (green) when stated as
onferred as (probably) consanguineous (PC); and discrepancy type C (red)
ferred as (probably) consanguineous. B: Number of individuals within each
tatus reported in the clinical record. Red dotted lines indicate the defined
; ROH, run of homozygosity.
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Consanguinity Detection for Diagnosisfiltering to variants within an ROH region (Figure 4A). The
candidate variants for each of these 79 cases were classified
according to ACMG criteria,29 and those in known disease-
causing genes were reported to the clinicians having sub-
mitted the cases to the RD-Connect GPAP. The clinicians
confirmed one of the variants was the cause of the disorder
in 41 cases (diagnostic rate Z 52%) (Figure 4B); in all
cases, it was a likely pathogenic or pathogenic variant, ac-
cording to ACMG criteria. In total, 28 of 44 cases (63.6%)
clinically reported and classified as consanguineous by our
model were solved; 9 of 19 (47.7%) only classified as
consanguineous by our model (discrepancies type B and C)
were solved, and 4 of 16 (25%) reported as consanguineous
and classified as uncertain or nonconsanguineous by our
model (discrepancy type A) were solved. Results from the
13 discrepant solved cases (discrepancy types A, B, and C)
are shown (Table 2. All causative variants from which pa-
tients were experimentally classified as consanguineous or
probably consanguineous (cases 1, 2, 4, 5, 8, 9, 10, 11, and
12) were found within ROH regions (>1 Mb). Patients from
cases 3, 6, 7, and 13 were reported as consanguineous but
not experimentally confirmed. In two of these patients
(cases 7 and 13), the causative variant was not found in an
ROH (Table 2).Figure 4 Combination of variant filtering and homozygosity mapping
to identify pathogenic variants. A: Comparison of the number of rare ho-
mozygous variants identified before and after combining variant filtering
with homozygosity mapping [ie, filtering to variants in run of homozygosity
(ROH) regions >1 megabase in length; P Z 1.179  107]. B: Distribution
of the 79 cases reported as consanguineous or classified as consanguineous
by our model. In blue, cases reported as consanguineous; and in red, cases
experimentally classified as probably consanguineous or consanguineous.
The intersection of both sections corresponds to 44 cases both reported
and experimentally classified as consanguineous. Discrepancy type A, in-
dividual stated as consanguineous in the clinical record but experimentally
conferred as uncertain or nonconsanguineous; discrepancy type B, when
status of consanguinity is unknown in the clinical record and experimen-
tally (probably) consanguineous; and discrepancy type C, when stated as
nonconsanguineous in the clinical record but experimentally (probably)
consanguineous. n Z 60 (B, cases reported as consanguineous); n Z 63
(B, cases experimentally classified as probably consanguineous or
consanguineous); n Z 44 (B, cases both reported and experimentally
classified as consanguineous).Discussion
Next-generation sequencing technologies, and more spe-
cifically ES, are increasingly used for diagnostics and
require methods and approaches to decrease the turnaround
time of mutation detection. Autozygosity is known to be
associated with an increased risk of genetic RD and is thus a
relevant factor to take into consideration when undertaking
clinical genetic studies. In this study, we present an
approach to detect consanguineous offspring from ES data
and increase the efficiency of molecular diagnosis by
combining variant filtering and homozygosity mapping. To
demonstrate the usefulness of this approach, we have
analyzed ES data from the RD-Connect GPAP.
We have established a model to determine if an individual
is likely to be a consanguineous offspring, according to the
total ROH size called by the PLINK software in the training
data set. Our model has enabled the classification of four
ranges: nonconsanguineous (total ROH size < 22 Mb or
Froh < 0.8%), uncertain (22 Mb < total ROH size < 79 Mb
or 0.8% < Froh < 2.9%), probably consanguineous (79 Mb
< total ROH size < 123 Mb or 2.9% < Froh < 4.6%), and
consanguineous (total ROH size > 123 Mb or Froh
> 4.6%). When tested with an independent data set, the
model showed high accuracy (97%), sensitivity (80%), and
specificity (99%). The consanguineous threshold we define
(Froh Z 4.6%) falls into the lower end of the CI
(Froh Z 4.6%e8.3%) reported for a third-degree consan-
guineous offspring using single-nucleotide polymorphism
arrays.30 This may be explained by the fact that ES has moreThe Journal of Molecular Diagnostics - jmd.amjpathol.orgdata points (single-nucleotide polymorphisms) than single-
nucleotide polymorphism arrays, thus enabling the usage
of 1-Mb length as minimum ROH segment for ES21 instead
of the 2 to 5 Mb recommended for single-nucleotide poly-
morphism arrays.30 These differences emphasize the rele-
vance of defining specific ROH (and Froh) thresholds for
each different genomic technique and the importance of
having specific ranges for ES data, as defined herein.
Because we did not identify any significant correlation with
the number of ROHs per individual, we did not include this
parameter in our model. However, size of the longest ROH
and its corresponding percentage from the total ROH size
per individual were checked to assess for any possible1211
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Matalonga et alcomplete uniparental disomy.31 In our cohort, 8 cases
(0.3%) presented an ROH >30 Mb and >30% of the total
ROH size for the sample. Although those individuals were
classified as (likely) consanguineous, we cannot discard the
prediction could be masked by the presence of uniparental
disomy or a large deletion.1212As demonstrated in our study, the proposed model is
independent from the sequencing facility, size, and type of
the exome capture kit used to perform ES as no variations
between total ROH size from nonconsanguineous in-
dividuals were observed between kits. Therefore, the
thresholds established herein for identification and reportingjmd.amjpathol.org - The Journal of Molecular Diagnostics
Consanguinity Detection for Diagnosisof possible offspring consanguinity can be applied in any
clinical laboratory, independent of the sequencing facility
and the library approach used for ES. However, the model
should be adapted if the data set to be tested is from a
population in which consanguinity may be elevated because
of culturally and socially favored consanguineous marriages
and/or geographic isolation.8 Our data set is strongly biased
toward European individuals, and similar studies still need
to be performed on larger ES data sets to set specific con-
sanguinity ranges by ethnicity as our results showed a ten-
dency toward increased total ROH size in Arabs and Asians.
Indeed, two of the cases incorrectly classified by our model
as consanguineous were of Asian origin. This result em-
phasizes the importance of recording ethnic and/or conti-
nental origin when submitting cases for molecular testing.
The analysis of the total ROH size distribution across
2432 ES data sets from the RD-Connect GPAP enabled us
to reclassify the consanguinity status of 12.8% of the pa-
tients, either through the detection of possible unstated
consanguinity or by challenging the consanguinity reported
in the corresponding clinical record. To highlight the utility
of this approach in molecular diagnostics, we have analyzed
and interpreted a subset of 79 index cases, looking for rare
homozygous variants within ROH regions (>1 Mb). The
analysis was done using the RD-Connect GPAP, which
enables the routine combination of variant filtering and
homozygosity mapping. Although this analysis focused
only on variants in known disease-causing genes, this
workflow may also be useful to identify new causative
genes. In experimentally classified consanguineous cases,
the number of candidate variants to be assessed was reduced
by 50% when filtering by ROH regions. This drastic
reduction of candidate variants facilitates and accelerates the
identification of causative variants by clinical geneticists.
After genomic analysis through the RD-Connect GPAP,
causative variants were identified and confirmed in 41 cases
(diagnostic rate Z 52%). All the causative variants from the
37 cases (92.5%) classified as consanguineous by our model
were found in an ROH region, supporting the fact that
filtering data from experimentally classified consanguineous
cases by ROH regions is a robust approach. Indeed, nine of
these solved cases (22.5%) were not declared as consan-
guineous in their clinical record, which might have had
misled geneticists as to which filtering approach to follow.
Four additional solved cases that were stated to be
consanguineous in the clinical record were not classified as
consanguineous by our model, with two being uncertain. In
two of the cases, the causative variants were found in an
ROH region; and in the other two cases, the causative
variants were not found in an ROH region. The former
could be indicative of more distant identical by descent
inheritance. We aimed to provide robust thresholds with
available tools to assess relatedness. Consequently, to
ensure proper sensitivity, consanguinity was defined for an
individual as being the offspring of up to third-degree (first
cousin) related parents. We are aware that more distantThe Journal of Molecular Diagnostics - jmd.amjpathol.orgidentical by descent might also be detectable with ROH
sizes falling in the gray area of the uncertain range. Thus,
when a more distant consanguinity is suspected, we also
encourage genomic analyses to start by performing a com-
bined ROH-genomic variants filtering approach. A patient’s
clinical diagnosis should also be taken into account before
undertaking this approach, as, for example, individuals with
severe developmental disorders are known to be enriched
for damaging de novo variants regardless of their level of
consanguinity.32
As the analytical approach described herein may lead to
the discovery of a consanguineous mating between the
proband’s parents, laboratories are encouraged to develop a
reporting policy to effectively and accurately communicate
these findings, as recommended by the ACMG guidelines.23
Therefore, the inclusion in laboratory reports of the total
ROH size and the corresponding experimental consan-
guinity classification described herein would help clinicians
to correlate laboratory results with family history and cul-
tural traditions and to investigate any concern of abuse, as
recommended by the ACMG.23
In summary, we have defined a method to identify and
easily report inbreeding within a pedigree from ES data,
enabling confirmation or (re)classification of consanguin-
eous status. Furthermore, we have implemented and
demonstrated the usefulness of combining variant filtering
and homozygosity mapping routinely in the RD-Connect
GPAP to filter to variants within ROH and thus facilitate
data filtering and interpretation. This method can be easily
implemented systematically in a clinical diagnostic setting
for data analysis and reporting, according to ACMG
guidelines regarding consanguinity as a secondary finding
of genomic testing.23 Altogether, the described approach
increases diagnostic yield and improves turnaround time,
hence reducing costs and contributing to the International
Rare Disease Research Consortium vision “to enable all
people living with a rare disease to receive an accurate
diagnosis, care and available therapy within one year of
coming to medical attention.”2,pp.21Acknowledgments
We thank Rare Disease (RD)eConnect Genome-Phenome
Analysis Platform and the Undiagnosed Rare Disease Pro-
gramme of Catalonia (URD-Cat) data contributors, who
have contributed the data used to perform the analysis
described in this study: Alessandra Renieri, Ali Dursun,
Antoni Matilla-Duenas, Bru Cormand, Carlo Rivolta, Car-
men Ayuso, Carmen Espinós, Christian Scerri, Dilek Yal-
nizoglu, Doriette Soler, Eva Morava, Fabrizio Barbetti,
Francesca Forzano, Francesca Mari, Francesco Muntoni,
Frederic Tort, Henry James Houlden, Maria-Isabel Tejada,
Jan Senderek, Javier Benitez, Javier Corral De La Calle,
Jordi Serra, José Ma Millán, Jose Segovia, Juan Ramon
Gimeno Blanes, Judith Armstrong, Koksal Ozgul, Laura1213
Matalonga et alVilarinho, Lluis Montoliu, Manuel Posada, Maria Anto-
nietta Mencarelli, Marina Mora, Paola Bianchi, Pavel See-
man, Perry M. Elliott, Alessandra Ferlini, Alexis Brice,
Brunhilde Wirth, Francesco Muntoni, Mike Hanna, Sarah
Tabrizi, Thomas Klockgether, Vincent Timmerman, Volker
Straub, Semra Hiz Kurul, Yavuz Oktay, Serdal Gungor,
Ahmet Yaramis, Uluc Yis, Alfons Macaya, Antonia Ribes,
Aurora Pujol, Conxi Lázaro, Daniel Grinberg, Eduardo
Tizzano, Francesc Cardellach, Francesc Palau, Montse Milà,
Pia Gallano, Rafael Artuch, Ramon MartiSeves, Gonzalo
Villanueva, Silvia Vidal, Gloria Garrabou, Susanna Bal-
cells, Roser Urreizti, Estrella López, Ivon Cuscó, Irene
Valenzuela, and Maria Sabater.Authors’ Contributions
L.M., S.L., and A.P. analyzed data (integration of SNV-
indel and ROH analysis); D.P. developed the Rare Disease
(RD)eConnect platform to integrate the analysis of ROH
data; E.M. designed the logistic regression model; G.B.
processed and analyzed Undiagnosed Rare Disease Program
of Catalonia samples; R.T., R.H., L.P.J., O.R., I.G.,
G.-J.v.O., and H.L. recruited patient/data and coordinated
molecular diagnosis feedback from each of the projects
involved in this study; S.B., S.L., and L.M. designed the
study and wrote the manuscript; all authors revised the
article and read and approved the final manuscript. L.M. and
S. B. are the guarantors of this work and, as such, had full
access to all of the data in the study and take responsibility
for the integrity of the data and the accuracy of the data
analysis.́
Supplemental Data
Supplemental material for this article can be found at
http://doi.org/10.1016/j.jmoldx.2020.06.008.References
1. Nguengang Wakap S, Lambert DM, Olry A, Rodwell C, Gueydan C,
Lanneau V, Murphy D, Le Cam Y, Rath A: Estimating cumulative
point prevalence of rare diseases: analysis of the Orphanet database.
Eur J Hum Genet 2020, 28:165e173
2. Austin CP, Cutillo CM, Lau LPL, Jonker AH, Rath A, Julkowska D,
Thomson D, Terry SF, de Montleau B, Ardigò D, Hivert V,
Boycott KM, Baynam G, Kaufmann P, Taruscio D, Lochmüller H,
Suematsu M, Incerti C, Draghia-Akli R, Norstedt I, Wang L,
Dawkins HJS; International Rare Diseases Research Consortium
(IRDiRC): Future of rare diseases research 2017-2027: an IRDiRC
perspective. Clin Transl Sci 2018, 11:21e27
3. Boycott KM, Hartley T, Biesecker LG, Gibbs RA, Innes AM, Riess O,
Belmont J, Dunwoodie SL, Jojic N, Lassmann T, Mackay D,
Temple IK, Visel A, Baynam G: A: Diagnosis for all rare genetic
diseases: the horizon and the next frontiers. Cell 2019, 177:32e37
4. Boycott KM, Hartley T, Biesecker LG, Gibbs RA, Innes AM, Riess O,
Belmont J, Dunwoodie SL, Jojic N, Lassmann T, Mackay D,
Temple IK, Visel A, Baynam G: International cooperation to enable1214the diagnosis of all rare genetic diseases. Am J Hum Genet 2017, 100:
695e705
5. Lochmüller H, Badowska DM, Thompson R, Knoers NV, Aartsma-
Rus A, Gut I, Wood L, Harmuth T, Durudas A, Graessner H,
Schaefer F, Riess O: RD-connect, NeurOmics and EURenOmics:
collaborative European initiative for rare diseases. Eur J Hum Genet
2018, 26:778e785
6. Thompson R, Johnston L, Taruscio D, Monaco L, Béroud C, Gut IG,
Hansson MG, ’t Hoen PB, Patrinos GP, Dawkins H, Ensini M,
Zatloukal K, Koubi D, Heslop E, Paschall JE, Posada M,
Robinson PN, Bushby K, Lochmüller H: RD-connect: an integrated
platform connecting databases, registries, biobanks and clinical bio-
informatics for rare disease research. J Gen Intern Med 2014, 29 Suppl
3:S780eS787
7. Ouborg NJ, Pertoldi C, Loeschcke V, Bijlsma RK, Hedrick PW:
Conservation genetics in transition to conservation genomics. Trends
Genet 2010, 26:177e187
8. Fareed M,, Afzal M: Genetics of consanguinity and inbreeding in
health and disease. Ann Hum Biol 2017, 44:99e107
9. Matthijs G, Rymen D, Millón MB, Souche E, Race V: Approaches to
homozygosity mapping and exome sequencing for the identification of
novel types of CDG. Glycoconj J 2013, 30:67e76
10. Vahidnezhad H, Youssefian L, Jazayeri A, Uitto J: Research tech-
niques made simple: genome-wide homozygosity/autozygosity map-
ping is a powerful tool for identifying candidate genes in autosomal
recessive genetic diseases. J Invest Dermatol 2018, 138:1893e1900
11. Posey JE, O’Donnell-Luria AH, Chong JX, Harel T, Jhangiani SN,
Coban Akdemir ZH, et al: Insights into genetics, human biology and
disease gleaned from family based genomic studies. Genet Med 2019,
21:798e812
12. Pippucci T, Magi A, Gialluisi A, Romeo G: Detection of runs of ho-
mozygosity from whole exome sequencing data: state of the art and
perspectives for clinical, population and epidemiological studies. Hum
Hered 2014, 77:63e72
13. Seelow D, Schuelke M, Hildebrandt F, Nürnberg P: Homo-
zygosityMapper–an interactive approach to homozygosity mapping.
Nucleic Acids Res 2009, 37:W593eW599
14. Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA,
Bender D, Maller J, Sklar P, de Bakker PI, Daly MJ, Sham PC:
PLINK: a tool set for whole genome association and population-based
linkage analyses. Am J Hum Genet 2007, 81:559e575
15. Görmez Z, Bakir-Gungor B, Sagiroglu MS: HomSI: a homozygous
stretch identifier from next-generation sequencing data. Bioinformatics
2014, 30:445e447
16. Magi A, Tattini L, Palombo F, Benelli M, Gialluisi A, Giusti B,
Abbate R, Seri M, Gensini GF, Romeo G, Pippucci T: H3M2:
detection of runs of homozygosity from whole-exome sequencing data.
Bioinformatics 2014, 30:2852e2859
17. Gibson J, Morton NE, Collins: Extended tracts of homozygosity in
outbred human populations. Hum Mol Genet 2006, 15:789e795
18. Ceballos FC, Joshi PK, Clark DW, Ramsay M, Wilson JF: Runs of
homozygosity: windows into population history and trait architecture.
Nat Rev Genet 2018, 19:220e234
19. Howrigan DP, Simonson MA, Keller MC: Detecting autozygosity
through runs of homozygosity: a comparison of three autozygosity
detection algorithms. BMC Genomics 2011, 12:460
20. Oliveira J, Pereira R, Santos R, Sousa M: Homozygosity mapping
using whole-exome sequencing: a valuable approach for pathogenic
variant identification in genetic diseases. Bioinformatics (Biostec)
2017, 3:210e216
21. Kancheva D, Atkinson D, De Rijk P, Zimon M, Chamova T, Mitev V,
Yaramis A, Maria Fabrizi G, Topaloglu H, Tournev I, Parman Y,
Parma Y, Battaloglu E, Estrada-Cuzcano A, Jordanova A: Novel
mutations in genes causing hereditary spastic paraplegia and Charcot-
Marie-Tooth neuropathy identified by an optimized protocol for ho-
mozygosity mapping based on whole-exome sequencing. Genet Med
2016, 18:600e607jmd.amjpathol.org - The Journal of Molecular Diagnostics
Consanguinity Detection for Diagnosis22. Masingue M, Perrot J, Carlier RY, Piguet-Lacroix G, Latour P,
Stojkovic T: WES homozygosity mapping in a recessive form of
Charcot-Marie-Tooth neuropathy reveals intronic GDAP1 variant
leading to a premature stop codon. Neurogenetics 2018, 19:67e76
23. Rehder CW, David KL, Hirsch B, Toriello HV, Wilson CM,
Kearney HM: American College of Medical Genetics and Genomics:
standards and guidelines for documenting suspected consanguinity as an
incidental finding of genomic testing. Genet Med 2013, 15:150e152
24. Laurie S, Fernandez-Callejo M, Marco-Sola S, Trotta JR, Camps J,
Chacón A, Espinosa A, Gut M, Gut I, Heath S, Beltran S: Fromwet-lab to
variations: concordance and speed of bioinformatics pipelines for whole
genome and whole exome sequencing. HumMutat 2016, 37:1263e1271
25. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM:
Robust relationship inference in genome-wide association studies.
Bioinformatics 2010, 26:2867e2873
26. Karczewski KJ, Francioli LC, Tiao G, Cummings BB, Alföldi J,
Wang Q, et al: The mutational constraint spectrum quantified from
variation in 141,456 humans. Nature 2020, 581:434e443
27. Lek M, Karczewski KJ, Minikel EV, Samocha KE, Banks E,
Fennell T, et al: Analysis of protein-coding genetic variation in 60,706
humans. Nature 2016, 536:285e291The Journal of Molecular Diagnostics - jmd.amjpathol.org28. 1000 Genomes Project Consortium, Auton A, Brooks LD, Durbin RM,
Garrison EP, Kang HM, Korbel JO, Marchini JL, McCarthy S,
McVean GA, Abecasis GR: A global reference for human genetic
variation. Nature 2015, 526:68e74
29. Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J,
Grody WW, Hegde M, Lyon E, Spector E, Voelkerding K, Rehm HL;
ACMG Laboratory Quality Assurance Committee: Standards and
guidelines for the interpretation of sequence variants: a joint consensus
recommendation of the American College of Medical Genetics and
Genomics and the Association for Molecular Pathology. Genet Med
2015, 17:405e424
30. Sund KL, Rehder CW: Detection and reporting of homozygosity
associated with consanguinity in the clinical laboratory. Hum Hered
2014, 77:217e224
31. Bis DM, Schüle R, Reichbauer J, Synofzik M, Rattay TW, Soehn A,
de Jonghe P, Schöls L, Züchner S: Uniparental disomy determined by
whole-exome sequencing in a spectrum of rare motoneuron diseases
and ataxias. Mol Genet Genomic Med 2017, 5:280e286
32. Deciphering Developmental Disorders Study: Prevalence and archi-
tecture of de novo mutations in developmental disorders. Nature 2017,
542:433e4381215
